MedTrace Logo

Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor

NCT01896284 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2018-11-23

No results posted yet for this study

Summary

Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of proangiogenic factors.

Conditions

  • Wet Macular Degeneration

Interventions

DRUG

0.5mg aflibercept

0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.

Sponsors & Collaborators

  • TFS Trial Form Support

    collaborator INDUSTRY

  • Bayer

    collaborator INDUSTRY

  • Barcelona Macula Foundation

    lead OTHER

Principal Investigators

  • Jordi Mones, MD PhD · Barcelona Macula Foundation

  • Carlos Juan Donate, MD · Hospital San Carlos, Madrid

  • Marta Suárez de Figueroa, MD · Hosipital Universitario Ramon y Cajal

  • Jose Luis Olea, MD · Hospital Son Espases

  • Francisco Cabrera, MD · Hospital Universitario Insular de Canarias

  • Laura Sarasols, MD · Hospital Universitari General de Catalunya

  • Javier Araiz, MD · Instituto Clínico Quirúrgico de Oftalmología de Bilbao

  • Jose Maria Ruiz-Moreno, MD · Hospital Universitario de Albacete

  • Ignasi Jürgens, MD PhD · Institut Catala de Retina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-11-30
Completion
2015-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01896284 on ClinicalTrials.gov